|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0030705,
umls-concept:C0035168,
umls-concept:C0076080,
umls-concept:C0086409,
umls-concept:C0086960,
umls-concept:C0205179,
umls-concept:C0282460,
umls-concept:C0442027,
umls-concept:C0549178,
umls-concept:C1257890,
umls-concept:C1261473,
umls-concept:C2603343
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2005-10-10
|
|
pubmed:abstractText |
The objective of this study was to evaluate the activity and toxicity of temozolomide given as an extended schedule in patients with advanced sarcoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
pubmed-author:BoverIsabelI,
pubmed-author:BuesaJose MJM,
pubmed-author:CasadoAntonioA,
pubmed-author:CruzJosefinaJ,
pubmed-author:Garcia del MuroXavierX,
pubmed-author:Lopez-PousaAntonioA,
pubmed-author:MartinJavierJ,
pubmed-author:Martinez-TruferoJavierJ,
pubmed-author:MaurelJoanJ,
pubmed-author:PovedaAndresA,
pubmed-author:Spanish Group for Research on Sarcomas
|
|
pubmed:copyrightInfo |
Copyright 2005 American Cancer Society
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
104
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1706-12
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16134177-Administration, Oral,
pubmed-meshheading:16134177-Adult,
pubmed-meshheading:16134177-Aged,
pubmed-meshheading:16134177-Antineoplastic Agents, Alkylating,
pubmed-meshheading:16134177-Dacarbazine,
pubmed-meshheading:16134177-Drug Administration Schedule,
pubmed-meshheading:16134177-Female,
pubmed-meshheading:16134177-Gastrointestinal Neoplasms,
pubmed-meshheading:16134177-Humans,
pubmed-meshheading:16134177-Liver Neoplasms,
pubmed-meshheading:16134177-Lung Neoplasms,
pubmed-meshheading:16134177-Male,
pubmed-meshheading:16134177-Maximum Tolerated Dose,
pubmed-meshheading:16134177-Middle Aged,
pubmed-meshheading:16134177-Prognosis,
pubmed-meshheading:16134177-Sarcoma,
pubmed-meshheading:16134177-Soft Tissue Neoplasms,
pubmed-meshheading:16134177-Survival Rate,
pubmed-meshheading:16134177-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas.
|
|
pubmed:affiliation |
Department of Medical Oncology, Institut Catala d'Oncologia, Institut d'Investigacio Bellvitge (IDIBELL), Barcelona, Spain. garciadelmuro@iconcologia.net
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
